49 results about "Retinal progenitor" patented technology

Methods are provided for the in vitro differentiation of human retinal progenitor cells from embryonic stem cells.

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

Methods are provided for the in vitro differentiation of human retinal progenitor cells from embryonic stem cells.

The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.

Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells. The subject matter described herein also provides cell populations comprising retinal progenitor cells and methods of isolation thereof.

Disclosed is a composition for inducing the proliferation of retinal cells or the differentiation of retinal progenitor cells into retinal cells. The composition, similar to in vivo conditions for development during embryogenesis, induces stem cells to differentiate into a multitude of photoreceptor cells at high yield within a short period of time, without an additional gene transfer. In addition, the differentiated photoreceptor cells are useful in cellular therapy because they, when transplanted into degenerated or injured retinas, can be engrafted and fused within the retinas to prevent or cure retinal degeneration.

The invention relates to a method for inducing a human pluripotent stem cell to differentiate into an RPE cell. According to the method, an inhibitor is used for inducing the human pluripotent stem cell to differentiate into a neural precursor; after Shh, IGF1 and EGF growth factors are utilized to activate ERK 1 / 2, JNK, Sonic hedgehog signal routes, the cell is presented as the shape of neuroepithelium, Activen A and Chir99021 are added to activate TGFbeta and Wnt signal routes respectively to induce a neuro-epithelial cell into a retinal progenitor cell; adherent culture is conducted on theretinal progenitor cell to obtain an RPE cell at an underdeveloped state. The invention further studies the field of applying the underdeveloped RPE cell to treating retinal degenerative diseases. Compared with the prior art, the method firstly makes three stages of differentiating the human pluripotent stem cell to the underdeveloped RPE cell and related small molecular substances and growth factors used therein clear. Compared with a matured RPE, the underdeveloped RPE obtained through differentiation can treat the retinal degenerative diseases more effectively after being transplanted.

The invention belongs to the field of biomedicine, and specifically relates to a method used for inducing differentiation of human multipotential stem cells into retinal progenitor cells. According to the method, human embryonic stem cells or human induced multipotential stem cells are induced in a medium containing N2, and then are delivered into a retina induction medium containing neural basis culture medium, knockout serum replacement and nicotinamide so as to obtain the retinal progenitor cells. The method is capable of increasing differentiation rate of human multipotential stem cells into retinal progenitor cells; and the retinal progenitor cells obtained via differentiation can be used for transplantation therapy of irreversible degenerative diseases of retinal neurons, such as age-related macular degeneration and retinitis pigmentosa, and also can be used for iPS cells sourced from patients as cell models in drug screening and gene interference experiments. Compared with existing technology, small molecule compounds used in the method are less, so that influences caused by non-anthropogenic factors are avoided effectively, and yield of obtained optic cup-like cells is obviously higher than that of existing induced differentiation methods.

The present invention relates to biocompatible compositions for transplantation into a sub-retinal space of the human eye. The compositions include a biodegradable polyester film, preferably a polycaprolactone (PCL) film, and a layer of human retinal progenitor cells. The compositions of the invention can be used as scaffolds for the treatment a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.

The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.

The invention relates to the bio-technical field, and discloses a cultural method for retina progenitor cells and a culture medium of the retina progenitor cells. According to the cultural method for cells disclosed by the invention, anchorage-dependent cells or suspension cells grow in an extracellular matrix with a certain three-dimensional space, so that so as to the growth velocity of cells is prevented effectively, cells are prevented from being aged or differentiated, the gene expression of the cells is not changed, high-quality and high-density cell reproduction is guaranteed and limitations of low yield of cells, poor quality of cells and the like in the traditional cultural method can be broken, so that the cultural method has a wide application prospect.

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

The invention provides a retinal progenitor cell generated by separating and inducing as well as a composition including the cell. The cell is transplanted to a host, so that integration rate and oncogenicity of the retina are greatly improved. The invention further provides a method of preparing the retinal progenitor cell by restraining a classical Wnt signal channel as well as a method of preparing the retinal progenitor cell suitable for transplanting. The invention further provides a composition consisting: (a), a Tcf1 protein, (b), a beta-catenin protein, and (c), a Sox2 protein as well as an application of the composition in screening a drug for lowering cell oncogenicity generated by inducing. The invention further provides a method of screening the drug for lowering cell oncogenicity generated by inducing. The invention opens up a novel way for cell treatment.

The invention discloses a method for preparing retinal progenitor cells derived from human pluripotent stem cells. The method comprises the following steps: selecting a 3d retinal cup which is subjected to induced differentiation for 50-60 days and derived from the human pluripotent stem cell, removing RPE and other non-3d retinal cup tissue, putting the retinal cup into a container with a liquidmedium, performing mechanical separation, separating and discarding a pigmentary layer of a dark and brown black part in the 3d retinal cup, retaining a nerve layer of a golden yellow part, further digesting the nerve layer into single cells, and putting the single cells into a culture plate which contains a RDM medium and is coated by Matrigel, so as to obtain the retinal progenitor cells. By adopting the method disclosed by the invention, 3d retinal tissue with stable quality can be obtained, retinal progenitor cells of which the number is controllable and the quality is controllable can beobtained, the time that the retinal progenitor cells are obtained can be shortened, obtaining procedures can be simplified, and the obtained retinal progenitor cells have good value increase performance and a capability of re-differentiated to other types of cells of retina.

The present invention provides a method of producing primate retinal progenitor cells, comprising culturing primate embryonic stem cells as suspended aggregates in a serum-free medium, and obtaining retinal progenitor cells from the culture. The present invention further provides a method of producing photoreceptor precursor cells, comprising culturing isolated retinal progenitor cells differentiated from embryonic stem cells, under adhesive conditions, in the presence of a gamma secretase inhibitor, and obtaining a photoreceptor precursor from the culture.

An object of the present invention is to provide a method of inducing pluripotent stem cells to differentiate into clinically applicable retinal ganglion cells.The present invention provides a method for inducing pluripotent stem cells to differentiate into retinal ganglion cells that can be used for clinical application. Such method is a method for producing retinal ganglion cells with elongated axons comprising the following steps: (a) a step of inducing pluripotent stem cells to differentiate into retinal progenitor cells via floating culture; (b) a step of inducing the retinal progenitor cells obtained in step (a) to differentiate into retinal ganglion cells via floating culture; and (c) a step of allowing axons to elongate via adhesion culture of the retinal ganglion cells obtained in step (b).

The present invention pertains to a method for in vitro obtaining human retinal progenitors, comprising the steps of (i) placing an adherent culture of human pluripotent stem cells in a pro-neural medium; and (ii) maintaining this culture in said pro-neural medium until the appearance of pigmented cells and / or of neuroepithelial-like structures. Advantageously, additional steps can be perfonned to obtain RPE cells and / or precursors of the neural retina.

The present invention provides a method for retaining the continuous epithelial structure of retinal tissue. The method includes culturing a retinal tissue in a culture medium containing: a methyl group donor or a substrate of a methyl group donor at a concentration that inhibits cellular differentiation of neuroretinal precursor cells; and a neurite outgrowth inhibitor at a concentration that inhibits neurite outgrowth.

The present invention provides a method for maintaining a continuous epithelial structure of a retinal tissue including culturing the retinal tissue in a medium comprising a methyl group donor or a substrate of the methyl group donor at a concentration at which cell differentiation of a neural retinal progenitor cell is suppressed, and a neurite extension inhibitor at a concentration at which neurite extension is suppressed.

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

The invention relates to the technical field of stem cells, in particular to a retinal progenitor cell and a preparation thereof having a function of treating degenerative retinal diseases. The preservation number of the retinal progenitor cell provided by the invention is CGMCC NO.10419; and the retinal progenitor cell, which can keep a good proliferation ability and stem cell properties, can take a good curative effect on treating the degenerative retinal diseases. Experiments show that the retinal progenitor cell that the preservation number is CGMCC NO.10419, as being injected into the vitreous cavities of RCS rats, can take a protective effect and achieve multi-focal visual electric-physiology display on retinal outer nuclear layer cells; and in dark adaptation, potential change conducted by retinal nerve photoreceptor cells in a retinal progenitor cell injection group is more obvious than that in a group which is just injected with an HBSS (Hanks balanced salt solution) buffer solution. A water maze test also indicates that the visual function of the rats in the retinal progenitor cell injection group is improved. In addition, all rats injected with the retinal progenitor cell that the preservation number is CGMCC NO.10419 are free from abnormity.

Methods for producing substantially pure cultures of human neural retinal progenitor cells, forebrain progenitor cells, and retinal pigment epithelial cells are disclosed. In addition, the successful differentiation of human embryonic stem cells and human induced pluripotent stem cells through the major developmental stages of human retinogenesis is disclosed.

The invention relates to an application of poly(sebacoyl diglyceride) in preparation of a retinal nerve cell carrier; retinal progenitor cells RPCs are proliferated, differentiated and migrated on the retinal nerve cell carrier, wherein a component of the retinal nerve cell carrier comprises poly(sebacoyl diglyceride) PSeD. The retinal nerve cell delivery carrier has the advantages of good biological compatibility, low cell inflammation expression, low cell apoptosis factor, and excellent neural differentiation promoting function.

The invention relates to the technical field of stem cells, and especially relates to a method and kit for identifying retinal progenitor cells capable of treating retinal degenerative change. The method comprises the following steps: culturing retinal progenitor cells to the logarithmic phase, and carrying out flow cytometry identification, wherein the retinal progenitor cells that meet the identification standards are capable of treating retinal degenerative change. The retinal progenitor cells identified by the provided method can maintain a good proliferation performance and stem cell characteristics and have a good curative effect when being applied to the treatment on retinal degenerative change. The experiment results show that after the retinal progenitor cells identified by the provided method are injected into the vitreous body cavities of RCS mice, the retinal outer nuclear layer cells are protected; the multifocal visual electrophysiology examination results show that the change of potential transmitted by retinal photoreceptor cells of the cell injection group is more prominent than the group, which is only injected with a HBSS buffer solution. The water maze experiment results also show that after injection, the visual performance of mice is improved.